Effectiveness of the new serotypes in the 13-valent pneumococcal conjugate vaccine

Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual s...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2011-11, Vol.29 (49), p.9127-9131
Main Authors: Miller, Elizabeth, Andrews, Nicholas J, Waight, Pauline A, Slack, Mary P.E, George, Robert C
Format: Article
Language:English
Subjects:
13-Valent vaccine
Age
Allergy and Immunology
Applied microbiology
Bacterial diseases
Bacteriology
Biological and medical sciences
children
confidence interval
Confidence intervals
England - epidemiology
Estimates
Fundamental and applied biological sciences. Psychology
Human bacterial diseases
Humans
Immunization Programs
Infant
Infectious diseases
Invasive pneumococcal disease
Laboratories
Medical sciences
Microbiology
Miscellaneous
Pneumococcal conjugate vaccine
Pneumococcal Infections - epidemiology
Pneumococcal Infections - prevention & control
Pneumococcal Vaccines - administration & dosage
Pneumococcal Vaccines - immunology
Population Surveillance
serotypes
Serotyping
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcus infections
Streptococcus pneumoniae
Streptococcus pneumoniae - classification
Studies
vaccination
Vaccination - statistics & numerical data
Vaccine effectiveness
Vaccines
Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
Vaccines, Conjugate - administration & dosage
Vaccines, Conjugate - immunology
Wales - epidemiology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights ► No direct evidence exists for effectiveness of the new serotypes covered by PCV13. ► Efficacy was presumed via a putative serological correlate of protection. ► One dose of PCV13 showed 70% efficacy against IPD caused by new serotypes. ► Protection also demonstrated against individual serotypes for 7F and 19A. ► 50% less IPD in children
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2011.09.112